May 27, 2025

New FDA approved Biosimilar Targets IL-12/23

The FDA has approved Starjemza, a ustekinumab biosimilar, for multiple inflammatory conditions.

Conexiant

May 27, 2025

Harvard Revokes Behavioral Research Tenure

Harvard Business School revokes tenure from Francesca Gino following data fraud allegations and an 18-month institutional investigation into research misconduct.

Conexiant

May 22, 2025

New FDA-Approved Topical Foam for Scalp Psoriasis

The FDA has approved roflumilast (ZORYVE) foam 0.3% for once-daily treatment of plaque psoriasis in patients aged 12 and older, including hard-to-treat scalp and body areas..

Conexiant

May 20, 2025

FDA Releases Guidance to Accelerate Generic Drugs

The new guidance is intended to “foster drug product development, ANDA submission and approval, and ultimately provide increased access to generic drugs."

Conexiant

May 19, 2025

Phase 3 Data Backs Roflumilast Foam

Roflumilast foam was found to improve scalp and body psoriasis symptoms with favorable tolerability in patients aged 12 years and older.

Conexiant

May 19, 2025

Bacteria Eat, Exploit Plastic: Study 

A hospital-derived strain of Pseudomonas aeruginosa was found to degrade medical plastic, use it as food, and form stronger biofilms, revealing new risks for device-related infections.

Conexiant

May 09, 2025

Psoriasis: Icotrokinra Shows Promise in Late-Stage Trial

Icotrokinra is designed to block a protein, IL-23, involved in inflammatory responses.

Reuters

May 09, 2025

Measles Cases Top 1,000 in U.S.

U.S. measles cases surpass 1,000 for the first time since 2019, with Texas at the center of the outbreak.

Reuters

May 05, 2025

Ustekinumab Biosimilar Receives Interchangeability Approval

Selarsdi (ustekinumab-aekn) was approved by the FDA as an interchangeable biosimilar to Stelara (ustekinumab) for all approved indications, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Conexiant